Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$110.94 USD

110.94
7,458,602

+1.05 (0.96%)

Updated Aug 15, 2024 04:00 PM ET

After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (99 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Abbott (ABT) Gets FDA Approval for Expanded Use of MitraClip

The FDA approval is expected to strengthen Abbott's (ABT) structural heart business.

Abbott (ABT) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Abbott (ABT) closed at $78.24, marking a +0.55% move from the previous day.

The Zacks Analyst Blog Highlights: Boeing, Abbott, PayPal, Caterpillar and Anthem

The Zacks Analyst Blog Highlights: Boeing, Abbott, PayPal, Caterpillar and Anthem

Mark Vickery headshot

Top Analyst Reports for Boeing, Abbott & PayPal

Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), Abbott (ABT) and PayPal (PYPL).

Here's Why You Should Snap Up Abbott (ABT) Stock Right Now

Synergies from Alere consolidation in the form of revenues from Abbott's (ABT) Rapid Diagnostics business have been driving growth.

DENTSPLY's (XRAY) Preliminary Q4 Results Cheer Investors

DENTSPLY (XRAY) expects to see solid performance in Europe and the rest of the world.

Here's Why You Should Buy Varian Medical (VAR) Stock Now

Buoyed by a strong first quarter, Varian Medical (VAR) has kept its fiscal 2019 guidance intact.

Merit Medical (MMSI) Q4 Earnings & Revenues Surpass Estimates

Merit Medical (MMSI) registers solid expansion in adjusted gross margins in fourth-quarter 2018.

Orthofix (OFIX) Earnings Beat Estimates in Q4, Margins Fall

Orthofix (OFIX) revenues across majority product lines witness year-over-year growth.

Veeva Systems (VEEV) Beats on Q4 Earnings and Revenues

Veeva Systems (VEEV) continues benefiting from its flagship Vault platform in fourth-quarter fiscal 2019.

Wright Medical (WMGI) Q4 Earnings & Revenues Beat Estimates

Wright Medical's (WMGI) top-line growth in fourth-quarter 2018 can be attributed to solid performance by the Upper and the Lower Extremities segments.

Bruker Rides on Robust NANO & CALID Groups, Recent Buyouts

Bruker's (BRKR) CALID and NANO groups hold promise.

Here's Why Investors Should Buy DexCom (DXCM) Stock Now

Solid growth at the Sensor, Transmitter and Receiver segments provide DexCom (DXCM) a competitive edge in the MedTech space.

Teleflex (TFX) Q4 Earnings Miss Estimates, Margins Rise

In Q4, Teleflex (TFX) registers strong growth in PICC, visual navigation products and EZ-IO.

Stryker Expands Acquisition Portfolio With Arrinex Buyout

Stryker's (SYK) latest buyout is expected to boost its Neurotechnology & Spine business.

CVS Health Rides on Aetna Synergy, PBM Selling Season Modest

With regard to its 2019 PBM selling season, CVS Health (CVS) notes that the net benefits from this selling season are expected to be modest on Anthem-related headwinds.

Chemed (CHE) Q4 Earnings Beat Estimates, Gross Margin Falls

Chemed's (CHE) Q4 revenues grow across key segments.

Quest Diagnostics Grows on Innovation Amid Reimbursement Woe

Quest Diagnostics' (DGX) progress in prescription drug monitoring, QuantiFERON and non-invasive prenatal screening are part of its recent major developments.

Why Is Abbott (ABT) Up 6% Since Last Earnings Report?

Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Investors Should Hold DaVita (DVA) Stock Now

DaVita (DVA) steadily expands in international markets. Moreover, the company has witnessed Dialysis services in the United States lately.

NuVasive (NUVA) Q4 Earnings Beat Estimates, Margins Fall

NuVasive (NUVA) reports growth in revenues across all key operating segments in the fourth quarter of 2018.

Abbott (ABT) Dips More Than Broader Markets: What You Should Know

Abbott (ABT) closed at $75.14 in the latest trading session, marking a -0.53% move from the prior day.

Medidata's (MDSO) Margins Under Pressure, Competition Rife

Medidata (MDSO) suffers from cutthroat competition in the clinical trial solutions market at the moment.

CVS Health's (CVS) Q4 Earnings Top Estimates, Margins Up

CVS Health's (CVS) recently introduced Health Care Benefits segment following the Aetna acquisition holds immense promise.

Intuitive Surgical Gets FDA Nod for Ion Endoluminal System

The regulatory go-ahead for the Ion platform is likely to provide Intuitive Surgical (ISRG) a competitive edge in the minimally-invasive-care space.